BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27171791)

  • 1. Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator.
    Iorizzo M; Hartmane I; Derveniece A; Mikazans I
    Skin Appendage Disord; 2016 Feb; 1(3):134-40. PubMed ID: 27171791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis.
    Piraccini BM; Iorizzo M; Lencastre A; Nenoff P; Rigopoulos D
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):917-929. PubMed ID: 32705532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis.
    Blume-Peytavi U; Tosti A; Falqués M; Tamarit ML; Carreño C; Galván J; Tebbs V
    Mycoses; 2022 Apr; 65(4):392-401. PubMed ID: 34752667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
    Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
    Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
    Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
    Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a fractional 2940-nm Er:YAG laser and 5% amorolfine lacquer combination therapy versus a 5% amorolfine lacquer monotherapy for the treatment of onychomycosis: a randomized controlled trial.
    Zhang J; Zhang Y; Qin J; Lu S; Cai W; Li J; Huang H; Yang S; Xi L
    Lasers Med Sci; 2021 Feb; 36(1):147-152. PubMed ID: 32557000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
    Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
    Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
    Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
    J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
    Schaller M; Sigurgeirsson B; Sarkany M
    Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs.
    Elewski BE; Ghannoum MA; Mayser P; Gupta AK; Korting HC; Shouey RJ; Baker DR; Rich PA; Ling M; Hugot S; Damaj B; Nyirady J; Thangavelu K; Notter M; Parneix-Spake A; Sigurgeirsson B
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):287-94. PubMed ID: 22181693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily Application of an Aqueous, Acidifying, Peelable Nail Polish versus Weekly Amorolfine for Topical Onychomycosis Treatment: A Prospective, Randomized, Blinded Trial.
    Eertmans F; Doss N; Rossel B; Adriaens E
    Dermatol Ther (Heidelb); 2018 Sep; 8(3):463-473. PubMed ID: 30051298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails.
    Ehrensberger M; Boal CWC; Brennan J; Barrett J; Makarus J; Callanan S; Spillane E; Patton T
    J Mycol Med; 2022 Aug; 32(3):101256. PubMed ID: 35219908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
    Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
    Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study.
    Lahfa M; Bulai-Livideanu C; Baran R; Ortonne JP; Richert B; Tosti A; Piraccini BM; Szepietowski JC; Sibaud V; Coubetergues H; Voisard JJ; Paul C
    Dermatology; 2013; 226(1):5-12. PubMed ID: 23467055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis.
    Rigopoulos D; Katoulis AC; Ioannides D; Georgala S; Kalogeromitros D; Bolbasis I; Karistinou A; Christofidou E; Polydorou D; Balkou P; Fragouli E; Katsambas AD
    Br J Dermatol; 2003 Jul; 149(1):151-6. PubMed ID: 12890209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How effective is topical miconazole or amorolfine for mild to moderately severe onychomycosis in primary care: the Onycho Trial - a randomised double-blind placebo-controlled trial.
    Watjer RM; Bonten TN; Sayed K; Quint KD; van der Beek MT; Mertens BJA; Numans ME; Eekhof JAH
    BMJ Open; 2024 May; 14(5):e081914. PubMed ID: 38702077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial comparing long-pulsed 1064-Nm neodymium: Yttrium-aluminum-garnet laser alone, topical amorolfine nail lacquer alone, and a combination for nondermatophyte onychomycosis treatment.
    Bunyaratavej S; Wanitphakdeedecha R; Ungaksornpairote C; Kobwanthanakun W; Chanyachailert P; Nokdhes YN; Patthamalai P; Tantrapornpong P; Suphatsathienkul P; Kiratiwongwan R; Limphoka P; Leeyaphan C
    J Cosmet Dermatol; 2020 Sep; 19(9):2333-2338. PubMed ID: 31925917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly.
    Reinel D; Clarke C
    Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():44-9. PubMed ID: 1458665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-blind Study of Amorolfine 5% Nail Lacquer with Oral Fluconazole Compared with Oral Fluconazole Alone in the Treatment of Fingernail Onychomycosis.
    Chandra S; Sancheti K; Podder I; Das A; Sarkar TK; Chowdhury M; Sil A; Bhattacharya S; Das NK
    Indian J Dermatol; 2019; 64(4):253-260. PubMed ID: 31516132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.